Special Issue "Vaccines against Hepatitis Viruses"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Hepatitis Virus Vaccines".

Deadline for manuscript submissions: 31 March 2021.

Special Issue Editor

Dr. Dirk Wohlleber
Guest Editor
Institute of Molecular Immunology, Technical University of Munich, 80333 Munich, Germany
Interests: liver immunology; viral hepatitis

Special Issue Information

Dear Colleagues,

Hepatitis viruses cause substantial morbidity and mortality worldwide. Immune therapy in the form of vaccination is considered the best option to prevent infection and the sequelae of chronic viral hepatitis, i.e., liver cirrhosis and liver cell cancer. Despite a prophylactic vaccination against Hepatitis B that efficiently protects against infection, numbers of patients with chronic hepatitis B did not decline over the last 10 years and more than 800,000 patients die from the consequences of chronic hepatitis every year. A therapeutic vaccination is therefore needed because no curative anti-viral treatment is available so far. For hepatitis C, a curative antiviral approach has been established, but a prophylactic vaccine is required to eradicate the Hepatitis C Virus and prevent the development of viral mutants. The high mutation rate of HCV renders vaccine development difficult. For hepatitis E, a prophylactic vaccine has been developed that also prevents fulminant viral hepatitis.

This issue focuses on the current research towards immunity against viral infections of the liver. Understanding the interaction of local immune cells in the liver with hepatocytes and non-parenchymal liver cells may be crucial in developing translational approaches to establish treatment strategies to overcome chronic viral hepatitis.

Dr. Dirk Wohlleber
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • HBV
  • HCV
  • chronic hepatitis
  • liver
  • immunology

Published Papers

This special issue is now open for submission.
Back to TopTop